Persistent disparities in diabetes medication receipt by socioeconomic disadvantage in Australia

It is unknown how use of newer glucose-lowering drugs (GLDs) has changed in Australia following the publication of clinical trials demonstrating definitive clinical advantages for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2is), and whet...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetic medicine 2022-06, p.e14898
Hauptverfasser:	Morton, Jedidiah I, Ilomӓki, Jenni, Magliano, Dianna J, Shaw, Jonathan E
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!